Filings & corporate actions
- 5 NovresultsResults · Q2 FY27 · standalone+7.9%NSE
- 17 OctshareholdingShareholding · 30 Sept 2026-1.2%NSE
- 10 AugresultsResults · Q1 FY27 · standalone+12.3%NSE
- 16 JulshareholdingShareholding · 30 Jun 2026+1.2%NSE
- 16 JuldividendDividend · ₹6.30 per share+1.2%
- 14 JulresultsResults · Q4 FY26 · consolidated and standalone-1.3%NSE
- 26 MayshareholdingShareholding · 18 May 2026+4.8%NSE
- 21 MayresultsResults · Q4 FY26 · consolidated and standalone+1.0%NSE
- 24 AprbuybackBuy Back-3.9%
- 15 AprshareholdingShareholding · 31 Mar 2026+6.4%NSE
- 5 FebresultsResults · Q3 FY26 · consolidated and standalone+2.0%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-5.7%NSE
Reaction to results · all yearsrose on day 0 in 12 of 22 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 5 Nov 2026 | +7.9% | +8.7% | — | 23.4× |
| Q1 FY27 | 10 Aug 2026 | +12.3% | +9.3% | +36.5% | 55.4× |
| Q4 FY26 | 21 May 2026 | +1.0% | +3.9% | +9.6% | 4.6× |
| Q3 FY26 | 5 Feb 2026 | +2.0% | -3.8% | -12.6% | 2.0× |
| Q2 FY26 | 6 Nov 2025 | -5.7% | -11.1% | -16.6% | 9.2× |
| Q1 FY26 | 12 Aug 2025 | +11.9% | +7.0% | +5.1% | 18.8× |
| Q4 FY25 | 22 May 2025 | -5.5% | -6.0% | -8.9% | 8.4× |
| Q3 FY25 | 11 Feb 2025 | +1.9% | -19.8% | +6.1% | 3.0× |
| Q2 FY25 | 12 Nov 2024 | +1.8% | -2.8% | +5.4% | 1.3× |
| Q1 FY25 | 13 Aug 2024 | -12.0% | -6.5% | +3.9% | 4.9× |
| Q4 FY24 | 20 May 2024 | +9.9% | +11.1% | +26.5% | 17.1× |
| Q3 FY24 | 8 Feb 2024 | -2.5% | -2.5% | +7.0% | 2.1× |
| Q2 FY24 | 8 Nov 2023 | -0.8% | +8.0% | +8.6% | 1.3× |
| Q1 FY24 | 9 Aug 2023 | +5.2% | +18.3% | +12.8% | 3.0× |
| Q4 FY23 | 6 May 2023 | +3.3% | +5.0% | +9.3% | 5.1× |
| Q3 FY23 | 9 Feb 2023 | +3.4% | +5.9% | +4.5% | 3.7× |
| Q2 FY23 | 9 Nov 2022 | -0.1% | -5.2% | +1.7% | 3.5× |
| Q1 FY23 | 4 Aug 2022 | -1.8% | -3.4% | +7.6% | 1.4× |
| Q4 FY22 | 12 May 2022 | +5.4% | +5.9% | +6.1% | 2.3× |
| Q3 FY22 | 3 Feb 2022 | -0.9% | +7.7% | -10.3% | 1.9× |
| Q2 FY22 | 2 Nov 2021 | -0.6% | -1.9% | -9.8% | 1.2× |
| Q1 FY22 | 8 Sept 2021 | -2.7% | -2.9% | -9.3% | — |
| Average | +1.5% | +1.1% | +4.0% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q4 FY26
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +18.9% | +20.8% | — | — | — | — |
| Profit | +4.4% | +12.6% | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions WINDLAS settled 50.1% of its traded quantity, which is above average for an NSE equity. Its one-year average is 53.9%, so recent sessions are running 3.7 points lower than usual. The latest session ranks higher than 66% of the 1,302 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -2.16% | -4.01% | +6.76% | -2.73% | +22.87% | +17.13% |
Valuation
Ownership
Quarterly results · consolidated
| Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 210.1 | 222.4 | 233.1 | 238.5 |
| YoY chg | +19.9% | +18.9% | +19.5% | +17.7% |
| Net profit (₹ Cr) | 17.7 | 17.8 | 15.0 | 16.0 |
| YoY chg | +31.0% | +13.7% | -3.7% | -1.8% |
| Net margin | 8.4% | 8.0% | 6.4% | 6.7% |
| EPS | 8.34 | 8.40 | 7.05 | 7.49 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 63.31% · public 36.69%- Promoter
- Public and others
- Promoter
- 63.31%
- Public
- 36.69%
- Promoter change
- 0.00 pp
- Filed
- 17 Oct 2026
- FII
- —
- DII
- —
- Promoter pledged
- —
Who the public is
- Mutual funds
- —
- Insurance
- —
- FPI
- —
- Retail ≤ ₹2L
- —
- HNI > ₹2L
- —
- NRI
- —
- Bodies corporate
- —
- Shareholders
- —
Major holders
As of 30 Jun 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited) | Promoter · Other | 40.61% | 83.81L |
| Ashok Kumar Windlass | Promoter · Individual | 21.32% | 44.00L |
| Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund | Mutual fund | 3.42% | 7.06L |
| Mncl Capital Compounder Fund 2 | AIF | 1.70% | 3.50L |
| Bandhan Small Cap Fund | Mutual fund | 1.43% | 2.95L |
| Vimla Windlasss | Promoter · Individual | 1.38% | 2.84L |
| Ajay Kumar Aggarwal | Individual | 1.21% | 2.49L |
| Perpetuity Health To Wealth (H2w) Rising Fund | AIF | 1.11% | 2.29L |
| Hitesh Windlass | Promoter · Individual | 0.00% | 3 |
| Manoj Kumar Windlass | Promoter · Individual | 0.00% | 3 |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
Dividends
| Financial year | Payments | Declared | Adjusted |
|---|---|---|---|
| FY2026-27 | 1 | ₹6.30 | ₹6.30 |
| FY2025-26 | 1 | ₹5.80 | ₹5.80 |
| FY2024-25 | 1 | ₹5.50 | ₹5.50 |
| FY2023-24 | 1 | ₹4.00 | ₹4.00 |
| FY2022-23 | 1 | ₹3.50 | ₹3.50 |
| Ex-date | Record date | Declared | Adjusted |
|---|---|---|---|
| 16 Jul 2026 | — | ₹6.30 | ₹6.30 |
| 21 Jul 2025 | — | ₹5.80 | ₹5.80 |
| 17 Sept 2024 | — | ₹5.50 | ₹5.50 |
| 5 Sept 2023 | — | ₹4.00 | ₹4.00 |
| 9 Sept 2022 | — | ₹3.50 | ₹3.50 |
Rupees per share by ex-date, from NSE’s corporate actions; the record date is who was paid. Declared is the figure in the filing; adjusted restates it for splits and bonuses since, on the same basis as the price chart. Financial years run April to March.
Bulk & block deals · 6 Nov 2026
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 6 Nov 2026 | Buy · bulk | STELLAR WEALTH PARTNERS INDIA FUND I LP | 1.50L | 1,020.42 | ₹15.4Cr |
| 11 Aug 2026 | Sell · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 1.19L | 936.43 | ₹11.1Cr |
| 11 Aug 2026 | Buy · bulk | NK SECURITIES RESEARCH PRIVATE LIMITED | 1.19L | 935.99 | ₹11.1Cr |
| 20 Feb 2025 | Buy · bulk | AJAY KUMAR AGGARWAL | 1.45L | 787.42 | ₹11.4Cr |
| 19 Feb 2025 | Sell · bulk | SAMVITTI CAPITAL PRIVATE LIMITED ACTIVE ALPHA MULTICAP | 1.15L | 683.49 | ₹7.9Cr |
| 1 Mar 2024 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 1.11L | 565.96 | ₹6.3Cr |
| 1 Mar 2024 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 1.11L | 564.94 | ₹6.3Cr |
| 8 Feb 2024 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 1.35L | 522.39 | ₹7.1Cr |
| 8 Feb 2024 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 1.35L | 522.27 | ₹7.1Cr |
| 2 Jan 2024 | Sell · bulk | GRAVITON RESEARCH CAPITAL LLP | 4.10L | 517.50 | ₹21.2Cr |
| 2 Jan 2024 | Buy · bulk | GRAVITON RESEARCH CAPITAL LLP | 4.10L | 517.17 | ₹21.2Cr |
| 2 Jan 2024 | Buy · bulk | JAINAM BROKING LIMITED | 1.50L | 511.50 | ₹7.7Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.
Exchange surveillance
No surveillance measure applies to WINDLAS.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures · band changes.
Every stock on this session →Financials · quarterly statement
| Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 144.8 | 152.7 | 162.2 | 171.3 | 175.2 | 187.0 | 195.0 | 202.7 | 210.1 | 222.4 | 233.1 | 238.5 | |
| Other income | 2.6 | 3.2 | 3.2 | 4.4 | 4.1 | 4.8 | 4.1 | 4.9 | 5.2 | 3.6 | 4.6 | 4.4 | |
| Total income | 147.4 | 155.9 | 165.4 | 175.7 | 179.3 | 191.8 | 199.1 | 207.6 | 215.3 | 226.0 | 237.7 | 242.8 | |
| Total expenses | 131.1 | 137.6 | 145.6 | 153.1 | 161.0 | 171.6 | 178.8 | 186.8 | 192.1 | 202.5 | 217.7 | 222.7 | |
| └ Finance costs | 0.2 | 0.3 | 0.3 | 0.3 | 0.5 | 1.1 | 1.5 | 1.3 | 1.1 | 1.0 | 1.3 | 1.5 | |
| └ Depreciation | 3.2 | 3.3 | 3.4 | 3.5 | 6.2 | 6.5 | 6.9 | 8.3 | 7.4 | 7.6 | 7.7 | 8.0 | |
| Profit before tax | 16.3 | 18.3 | 19.8 | 22.6 | 18.3 | 20.3 | 20.3 | 20.8 | 23.3 | 23.6 | 20.0 | 20.2 | |
| Tax expense | 4.3 | 4.3 | 4.7 | 5.6 | 4.8 | 4.6 | 4.8 | 4.5 | 5.6 | 5.8 | 5.0 | 4.2 | |
| Net profit | 12.1 | 14.0 | 15.1 | 17.0 | 13.5 | 15.7 | 15.6 | 16.3 | 17.7 | 17.8 | 15.0 | 16.0 | |
| EPS | 5.79 | 6.75 | 7.26 | 8.17 | 6.47 | 7.49 | 7.45 | 7.77 | 8.43 | 8.48 | 7.12 | 7.58 | |
| Net margin | 8.33% | 9.19% | 9.31% | 9.92% | 7.70% | 8.37% | 7.99% | 8.03% | 8.41% | 8.00% | 6.44% | 6.70% | |
| PBT margin | 11.29% | 11.99% | 12.21% | 13.21% | 10.45% | 10.85% | 10.43% | 10.27% | 11.07% | 10.61% | 8.57% | 8.45% | |
| Tax rate | 26.16% | 23.38% | 23.77% | 24.92% | 26.39% | 22.81% | 23.41% | 21.81% | 24.05% | 24.54% | 24.88% | 20.69% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 21 May 2026.
Balance sheet & cash flow · half-yearly
Balance sheet
| H1 FY23 | FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 518.2 | 529.0 | 570.0 | 626.2 | 746.9 | 760.5 | 814.2 | 907.3 | |
| Current assets | 404.3 | 353.5 | 388.4 | 431.3 | 517.2 | 525.1 | 563.5 | 626.9 | |
| └ Cash & equivalents | 21.9 | 3.7 | 1.2 | 5.3 | 0.4 | 0.4 | 0.2 | 0.5 | |
| └ Other bank balances | 78.6 | 21.8 | 26.3 | 25.7 | 31.1 | 15.5 | 14.8 | 1.3 | |
| └ Current investments | 78.9 | 106.5 | 141.2 | 173.4 | 181.6 | 223.4 | 245.6 | 268.4 | |
| └ Trade receivables | 105.3 | 116.9 | 127.4 | 136.3 | 186.8 | 166.9 | 197.8 | 227.4 | |
| └ Inventories | 82.2 | 74.7 | 61.1 | 62.2 | 82.0 | 81.4 | 70.3 | 61.8 | |
| Total equity | 408.3 | 402.3 | 416.2 | 449.9 | 471.2 | 505.8 | 534.1 | 580.8 | |
| └ Attributable to owners | 408.3 | 402.3 | 416.2 | 449.9 | 471.2 | 505.8 | 534.1 | 580.8 | |
| └ Non-controlling interest | — | — | — | 0.0 | — | — | 0.0 | — | |
| └ Share capital | 10.9 | 10.5 | 10.4 | 10.4 | 10.5 | 10.5 | 10.5 | 10.6 | |
| Borrowings | 0.6 | 0.4 | 2.2 | 0.1 | 15.2 | 27.1 | 25.9 | 29.9 | |
| └ Current | 0.4 | 0.3 | 2.2 | 0.1 | 15.2 | 27.1 | 25.9 | 29.9 | |
| └ Non-current | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Trade payables | 78.6 | 87.7 | 107.2 | 131.5 | 187.9 | 167.2 | 192.9 | 238.5 | |
| Current liabilities | 106.7 | 121.2 | 148.7 | 171.8 | 270.9 | 249.4 | 273.3 | 320.9 | |
| Total liabilities | 109.9 | 126.7 | 153.9 | 176.3 | 275.7 | 254.7 | 280.1 | 326.5 | |
| Net debt | (178.8) | (131.5) | (166.4) | (204.3) | (197.9) | (212.2) | (234.7) | (240.3) | |
| Debt / equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.03 | 0.05 | 0.05 | 0.05 | |
| Current ratio | 3.79 | 2.92 | 2.61 | 2.51 | 1.91 | 2.11 | 2.06 | 1.95 |
Cash flow, year to date
| H1 FY23 | FY23 | H1 FY24 | FY24 | H1 FY25 | FY25 | H1 FY26 | FY26 | Trend | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 20.9 | 61.0 | 53.7 | 109.0 | 29.7 | 68.2 | 55.9 | 104.9 | |
| └ Capex | (11.2) | (70.9) | (15.6) | (37.7) | (31.1) | (52.2) | 0.0 | (67.7) | |
| Free cash flow | 9.7 | (9.9) | 38.1 | 71.3 | (1.5) | 16.0 | 55.9 | 37.3 | |
| Investing cash flow | 15.5 | (14.1) | (44.5) | (92.1) | (37.4) | (74.1) | (43.8) | (91.8) | |
| Financing cash flow | (15.1) | (43.7) | (11.8) | (15.3) | 2.8 | 1.0 | (12.4) | (13.0) | |
| └ Dividends paid | (7.6) | (7.6) | (8.3) | (8.3) | 0.0 | (11.5) | (12.2) | (12.2) | |
| └ Buybacks | 0.0 | 0.0 | (4.0) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net change in cash | 21.3 | 3.1 | (2.5) | 1.6 | (4.9) | (4.9) | (0.2) | 0.1 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →WINDLAS at a glance
- WINDLAS closed at ₹961.25 on 20 Nov 2026, -2.16% on the day, +17.1% over one year, 18.7% below its 52-week high of ₹1,181.9.
- Delivery was 57.6% of traded quantity on 20 Nov 2026, the 66th percentile of its own 1,302 sessions with a reading (20-session average 50.1%, 1-year average 53.9%).
- Market capitalisation is ₹1,984 crore at a trailing P/E of 29.8 (trailing EPS ₹32.31).
- Q4 FY26 results (consolidated, filed 21 May 2026): revenue ₹238 crore (+17.7% year on year), net profit ₹16 crore (-1.8%); the price moved +1.0% on the first session after.
- Promoters held 63.31% at 30 Sept 2026, unchanged on the previous filing.
- Q3 FY27 results are expected between 3 Feb 2027 and 11 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE